Guy Yachin


Mr. Yachin is currently the CEO of Serpin Pharma Inc., a privately held, clinical stage Biotech Company in Virginia. Mr. Yachin is a serial entrepreneur who has served as CEO for numerous biomedical companies. His notable achievements include serving as the CEO of MGVS during collaborative funding with Teva Pharmaceuticals in 2009 and co-founding Chiasma Inc. which entered into a $600MM licensing agreement with Roche in 2013. He is the former CEO of Naiot Technological Center in Israel where he played an active role in establishing, managing and raising over $50M for over a dozen biomedical startup companies. As CEO of NasVax Ltd. he successfully led the company’s capital acquisition efforts on the public and private markets. Mr. Yachin has sat on the board of multiple companies including Orgenesis, Remon Medical Technologies, Enzymotec and NanoPass. He holds a BSc. and an MBA from Technion – Israel Institute of Technology.

Nitin Kaushal


Mr. Kaushal is a Managing Director in the Deals practice at PwC Canada. Nitin has more than 25 years experience in the financial investing, life sciences, consumer health care, health care services and medical device industries. His experience includes board of directorships with pharmaceutical and health care companies. He has also held senior roles in investment banking, venture capital and consulting firms. Nitin has performed over 50 merger, acquisition, strategic advisory, and licensing assignments. He has been an advisor to many of the leading global pharma companies and has participated in capital market transactions raising in excess of $2Bn.

Nancy Retzlaff


Nancy Retzlaff is a seasoned biopharmaceutical executive with over 20 years of experience. She began her career in the pharmaceutical industry with Bayer Healthcare in Canada and has since has since held commercial leadership positions of increasing responsibility at Bayer US, Schering-Plough and Pfizer. She has also held senior level positions at two start-up biopharma organizations. Nancy brings a track record of leading successful product launches globally as well as in the US, Europe, Japan & Canada, and has led a number of high profile brands including Cipro, Remicade, Lyrica, Aricept and Eliquis. She has broad therapeutic expertise in pain, immunology, neurosciences, infectious diseases and cardiology. Her deep commercial experience spans early commercial development through to life cycle management. Nancy has also served as an advisor to global pharma as well as early start-up companies.

Soren Mogelsvang, PhD

Director, President and CEO

Dr. Mogelsvang is a biotech executive and entrepreneur with over 15 years of experience. He is the co-founder of several biotech companies and brings a track record in building and leading privately funded and publicly traded companies. Recent positions he has held include President and CEO of Peak Pharmaceuticals, which he built from concept to a profitable veterinary health company; Co-founder and VP of R&D at Serpin Pharma, a clinical stage biotech company; Co-founder and Head of R&D at Caerus Discovery, an immunology company launched with support from BioWa – Kyowa Hakko Kirin and ImmunoCellular Therapeutics; Head of Cell Biology at ATCC; and Director of Laboratory and Production at Affinity BioReagents. Soren has PhD in Biochemistry (Cambridge, UK), and an MSc in Plant Molecular Biology (University of Copenhagen, Denmark).